Baillie Gifford & Co. Trims Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Baillie Gifford & Co. lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,358,581 shares of the company’s stock after selling 131,067,285 shares during the period. Baillie Gifford & Co. owned approximately 6.04% of Ginkgo Bioworks worth $27,372,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new stake in shares of Ginkgo Bioworks during the second quarter worth about $3,391,000. Monaco Asset Management SAM purchased a new stake in shares of Ginkgo Bioworks during the second quarter worth $3,276,000. Renaissance Technologies LLC acquired a new stake in shares of Ginkgo Bioworks in the second quarter valued at $2,128,000. Cetera Investment Advisers boosted its holdings in Ginkgo Bioworks by 2,683.7% in the first quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company’s stock valued at $2,626,000 after purchasing an additional 2,182,773 shares during the period. Finally, XTX Topco Ltd acquired a new position in Ginkgo Bioworks during the 2nd quarter worth $312,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

DNA stock opened at $8.36 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.26 and a twelve month high of $75.20. The business’s 50 day moving average is $7.70.

Wall Street Analysts Forecast Growth

DNA has been the subject of several recent research reports. TD Cowen lifted their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 20th. BTIG Research lifted their price objective on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Ginkgo Bioworks has a consensus rating of “Hold” and a consensus target price of $4.16.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.